Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 70 of 228 for:    EDN1

Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation (HEAD-MET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03510390
Recruitment Status : Recruiting
First Posted : April 27, 2018
Last Update Posted : June 7, 2019
Sponsor:
Collaborators:
University of Bern
Werner und Hedy Berger-Janser – Stiftung
Information provided by (Responsible Party):
University Hospital Inselspital, Berne

Brief Summary:

The study evaluates the effects of the drug Metformin on the oxygen content in cancer tissue. Low oxygen concentration in cancer tissue accelerates cancer growth. Moreover, the response to radiation therapy is worse when tissue oxygen is low, because radiation therapy depends on oxygen to unfold therapeutic effects. Metformin has been used to treat type II diabetes for over 50 years and features additional properties that could slow down cancer growth. One of these properties is the improved oxygen concentration in cancer tissue. This effect has been proven for various cancers.

This study was planned to verify this effect in head and neck cancer. Patients who suffer from cancer of the mouth and are planned for surgical removal of the cancer will be given Metformin for 9 to 14 days. The tissue removed in the subsequent surgery will be compared to a tissue sample that had been taken from the same patient prior to Metformin intake. To evaluate the oxygen content in the tissue samples, the expression of genes that react to oxygen levels will be measured and compared between the samples taken before and after treatment with Metformin.

A secondary aim is to evaluate whether changes in the oxygen content within the tumor can be visualized by means of magnetic resonance imaging (MRI). Therefore, participants undergo an MRI scan, before and after Treatment with Metformin. The changes in the MRI will be correlated to the changes measured in gene expression.


Condition or disease Intervention/treatment Phase
Head and Neck Cancer Oral Cavity Squamous Cell Carcinoma Drug: Metformin Not Applicable

Detailed Description:

The main objective of this trial is to prove the hypothesis that Metformin reduces tissue hypoxia in oral cavity squamous cell carcinoma after a course of treatment of 9-14 days.

The primary endpoint of the trial is the change in hypoxia-regulated gene expression upon Treatment with Metformin. Secondary endpoint are changes in MRI imaging correlating with the changes in gene expression.

Study design: This is a single-arm, open-label interventional window of opportunity study for proof of principle. Oral cavity squamous cell carcinoma is primarily treated by surgical tumor resection. This offers the possibility to study the effect of metformin on the tumor tissue.

Baseline tissue from potential participants before the intervention will be acquired by biopsy during diagnostic panendoscopy. Provided surgery is recommended by tumor board decision, participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days, depending on the date of the planned surgery. The resected tumor tissue as well as the biopsy taken prior to metformin treatment will be subjected to massive parallel sequencing and immunohistochemistry.

To assess whether changes in hypoxia regulated gene expression can be correlated to changes in MRI scans, each participants will undergo a MRI scan before metformin treatment and a second MRI scan within 48 hours prior to the surgical resection of the tumor.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Window-of-opportunity
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation
Actual Study Start Date : June 13, 2018
Estimated Primary Completion Date : September 15, 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Metformin
Participants will be orally administered 850 mg of metformin twice daily between the therapeutic decision of the tumor board and the surgical resection of the tumor. The duration of the treatment is 9-14 days
Drug: Metformin
850 mg, oral, twice daily, 9-14 days




Primary Outcome Measures :
  1. Metformin dependent changes in gene expression [ Time Frame: Baseline and two weeks ]

    Metformin induced changes in gene expression between samples taken before and after the intervention, analyzed by RNAseq, with special attention to hypoxia responsive genes:

    • Hypoxia inducible factor 1 (HIF1) and co-transcription factors (ARNT, COPS5, HIF1A, HIFAN, HIF3a, HNF4A, NCOA1, PER1)
    • HIF interactors (APEX1, EGLN1, EGLN2, NFKB1, P4HA1, P4HB, TP53)
    • Markers of Angiogenesis (ADROA2B, ANGPTL4, ANXA2, BTG1, EGR1, EDN1, EPO, F3, GPI, HMOX1, JMJD6, LOX, MMP9, PGF, PLAU, SERPINE1, VEGFA)

    Additionally, metformin induced changes in HIF1A, Ki67, cleaved caspase 3, CAIX, p-mTOR and p-AKT will be assessed by immunohistochemistry



Secondary Outcome Measures :
  1. Hypoxia dependent changes in MRI [ Time Frame: baseline and two weeks ]
    Diffusion-weighted MRI and blood oxygen level dependent imaging (BOLD) will be obtained before and after the Intervention and compared. Alterations will be correlated to changes in gene Expression.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with biopsy-proven oral cavity squamous cell carcinoma, planned for tumor resection upon institutional tumor board decision.
  • Tumor tissue (biopsy) prior to metformin administration available for genetic testing
  • Age ≥ 18 years of age.
  • First diagnosis, no prior treatment.
  • All subjects must be able to comprehend and sign a written informed consent document.
  • Informed consent as documented by signature

Exclusion Criteria:

  • Pregnancy or lactation.
  • Distant metastasis.
  • Hypersensitivity to metformin or any of its components.
  • Metformin treatment for any reason during the preceding 3 months.
  • Diabetic patients regardless of treatment.
  • Patients planned for imaging using iodinated contrast dye within 16 days prior to surgery.
  • Any concomitant drug contraindicated for use with metformin according to the approved product information.
  • Plasma alanine aminotransferase > 50 IU/dL.
  • Plasma aspartate aminotransferase > 50 IU/dL.
  • Estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2.
  • Plasma alkaline phosphatase greater than 190 IU/dL.
  • History of lactic or any other metabolic acidosis.
  • History of diseases potentially causing tissue hypoxia and/or increased risk of lactic acidosis:
  • Congestive heart failure.
  • Myocardial ischemia within the last 6 months
  • Sepsis or severe infection.
  • History of lung disease currently requiring any pharmacologic or supplemental oxygen treatment.
  • History of hepatic dysfunction or hepatic disease.
  • Chronic alcoholism which poses a risk for acute alcohol intoxication at the discretion of the treating physician.
  • Scheduled definitive surgical resection less than 10 days from enrollment.
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment, affect patient compliance or place the patient at high risk from treatment-related complication
  • Known or suspected non-compliance.
  • Participation in another study with investigational drug within the 30 days preceding and during the present study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03510390


Contacts
Layout table for location contacts
Contact: Olgun Elicin, MD +41316322431 olgun.elicin@insel.ch
Contact: Simon Mueller, MD +41316322931 simon.mueller@insel.ch

Locations
Layout table for location information
Switzerland
Inselspital, Bern University Hospital Recruiting
Bern, Switzerland, 3010
Contact: Olgun Elicin, MD    +41316322431    olgun.elicin@insel.ch   
Contact: Simon Mueller, MD    +41316322931    simon.mueller@insel.ch   
Sponsors and Collaborators
University Hospital Inselspital, Berne
University of Bern
Werner und Hedy Berger-Janser – Stiftung
Investigators
Layout table for investigator information
Principal Investigator: Olgun Elicin, MD University Hospital Inselspital, Bern, Switzerland
Principal Investigator: Simon Mueller, MD University Hospital Inselspital, Bern, Switzerland

Layout table for additonal information
Responsible Party: University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier: NCT03510390     History of Changes
Other Study ID Numbers: 3598
First Posted: April 27, 2018    Key Record Dates
Last Update Posted: June 7, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University Hospital Inselspital, Berne:
head and neck cancer
tissue hypoxia
metformin
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs